Pfizer compound PF-3758309, initially designed to be a PAK4-specific ATP-competitive inhibitor, disrupted PAK4-dependent cell adhesion and anchorage-independent growth in MDA-MB-231 xenograft tumour models, corresponding to an 89% reduction in BCa tumour growth (Murray et al., 2010). The gene discussed is PAK4; the disease is neoplasm.